BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23290205)

  • 1. A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.
    Ismail Z; Emeremni CA; Houck PR; Mazumdar S; Rosen J; Rajji TK; Pollock BG; Mulsant BH
    Am J Geriatr Psychiatry; 2013 Jan; 21(1):78-87. PubMed ID: 23290205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
    Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressants for agitation and psychosis in dementia.
    Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
    Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
    Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
    Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
    Ho T; Pollock BG; Mulsant BH; Schantz O; Devanand DP; Mintzer JE; Porsteinsson AP; Schneider LS; Weintraub D; Yesavage J; Drye LT; Munro CA; Shade DM; Lyketsos C; Bies R
    Br J Clin Pharmacol; 2016 Sep; 82(3):784-92. PubMed ID: 27145364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
    Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial.
    Culo S; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Pollock BG
    Alzheimer Dis Assoc Disord; 2010; 24(4):360-4. PubMed ID: 20625270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
    Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
    Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
    Weintraub D; Drye LT; Porsteinsson AP; Rosenberg PB; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Yesavage J; Lyketsos CG;
    Am J Geriatr Psychiatry; 2015 Nov; 23(11):1127-33. PubMed ID: 26238225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
    Peters ME; Vaidya V; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Avramopoulos D;
    J Geriatr Psychiatry Neurol; 2016 Mar; 29(2):59-64. PubMed ID: 26303700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
    Rabinowitz J; Katz I; De Deyn PP; Greenspan A; Brodaty H
    Int Psychogeriatr; 2007 Apr; 19(2):227-40. PubMed ID: 16879763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances.
    Suh GH; Son HG; Ju YS; Jcho KH; Yeon BK; Shin YM; Kee BS; Choi SK
    Am J Geriatr Psychiatry; 2004; 12(5):509-16. PubMed ID: 15353389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
    De Deyn PP; Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():19-22. PubMed ID: 11584983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
    Freund-Levi Y; Jedenius E; Tysen-Bäckström AC; Lärksäter M; Wahlund LO; Eriksdotter M
    Am J Geriatr Psychiatry; 2014 Apr; 22(4):341-8. PubMed ID: 24035407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
    Ostinelli EG; Hussein M; Ahmed U; Rehman FU; Miramontes K; Adams CE
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD009412. PubMed ID: 29634083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.